SCHEMBL26985024

SCHEMBL26985024

COC(=O)c1cncc(Nc2ccc(Cl)cc2F)c1C(F)(F)F

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ NUDT1 P36639 5/20 0.53
▸ TGFBR1 P36897 2/20 0.46
▸ CSF1R P07333 1/20 0.43
▸ ACVR1B P36896 1/20 0.40
▸ ACVRL1 P37023 1/20 0.40
▸ EGFR P00533 1/20 0.39
▸ ABL1 P00519 1/20 0.39
▸ MAPK10 P53779 2/20 0.39
▸ CNR2 P34972 1/20 0.38
▸ DHODH Q02127 1/20 0.38
▸ MAP2K1 Q02750 2/20 0.38
▸ FGFR1 P11362 1/20 0.37
▸ FLT1 P17948 1/20 0.37
▸ EPHB2 P29323 1/20 0.37
▸ FLT4 P35916 1/20 0.37
▸ KDR P35968 1/20 0.37
▸ SOS1 Q07889 1/20 0.37
▸ ALPL P05186 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30746560 1.00 NUDT1 (0.53) NUDT1TGFBR1CSF1RACVR1BACVRL1
SCHEMBL30746391 0.87 NUDT1 (0.53) NUDT1TGFBR1CSF1RCNR2MAP2K1
SCHEMBL26985321 0.87 NUDT1 (0.53) NUDT1TGFBR1CSF1RCNR2MAP2K1
SCHEMBL26984900 0.85 NUDT1 (0.56) NUDT1TGFBR1CSF1RACVR1BACVRL1
SCHEMBL30746487 0.85 NUDT1 (0.56) NUDT1TGFBR1CSF1RACVR1BACVRL1
SCHEMBL30746686 0.76 NUDT1 (0.43) NUDT1CSF1REGFRCNR2MAP2K1
SCHEMBL26985203 0.76 NUDT1 (0.43) NUDT1CSF1REGFRCNR2MAP2K1
SCHEMBL30746436 0.74 NUDT1 (0.40) NUDT1EGFRCNR2FGFR1FLT1
SCHEMBL26985312 0.74 NUDT1 (0.40) NUDT1EGFRCNR2FGFR1FLT1
SCHEMBL15239842 0.73 TGFBR1 (0.45) NUDT1TGFBR1ABL1ALPL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260001845-A1 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS NESTED THERAPEUTICS INC (US) 2026-01-01 — — US disclosed
US-20250288571-A1 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS NESTED THERAPEUTICS, INC. 2025-09-18 — — US disclosed
WO-2024010925-A2 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS NESTED THERAPEUTICS, INC. (US) 2024-01-11 — — WO disclosed
WO-2024010925-A2 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS NESTED THERAPEUTICS, INC. (US) 2024-01-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260001845-A1 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS MAPK6, MAPK3, MAPK1 NUDT1 1810/4885TGFBR1 1219/4885CSF1R 3256/4885
US-20250288571-A1 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS BRAF, MAP3K1, MAP3K5 NUDT1 2559/4885TGFBR1 2807/4885CSF1R 1602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback